Source: Annual Congress 2011 - Novel mechanisms in lung injury
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
U. Farkhutdinov, S. Farkhutdinov (Ufa, Russian Federation). Ceruloplasmine efficacy in patients with asthma exacerbations. Eur Respir J 2011; 38: Suppl. 55, 3912

Member's Comments

No comment yet.

Related content which might interest you: Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 COPD patients with asthma, characteristics and risk of exacerbations Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Efficacy and safety of intravenous montelukast in patients with acute exacerbations of bronchial asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Perceived bronchodilator efficacy during severe asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 The effect of bronchiectasis on asthma exacerbations Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Magnetocardiographic assessment of therapeutic efficacy of β2–agonists and corticosteroids in patients with COPD and bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Could montelukast reduce asthma exacerbations? Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 The impact of bronchiectasis on outcomes in a large cohort of patients hospitalised with exacerbations of COPD Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013